Vétoquinol UK has announced that Forcyl, the only patented 16% marbofloxacin formulation, is now indicated for the intravenous treatment of acute E.coli mastitis as a Single Injection Short Acting AntiBiotic (SiSAAB).

Vétoquinol UK has announced that Forcyl, the only patented 16% marbofloxacin formulation, is now indicated for the intravenous treatment of acute E.coli mastitis as a Single Injection Short Acting AntiBiotic (SiSAAB).

Forcyl now indicated for Acute E.coli mastitisThe SiSAAB concept is based on increasing the dose for quick and highly concentrated bactericidal effect, while reducing the treatment duration to a single administration to minimise the risk of resistance development.  

According to Vétoquinol, Forcyl is an innovative formulation with a lower volume of administration and an improved injection site tolerance, and is a highly effective treatment choice for E.coli mastitis with a fast clinical improvement and an optimal return to milk production.  

The recommended dose rate is a single injection, of 10mg/kg bodyweight i.e. 10ml/160kg. 

Senior product manager Susan Nash said: “The new indication enables the SiSAAB concept to be demonstrated effectively in E.coli mastitis situations where speed of action and cure rates are essential. 

“The SiSAAB concept minimises the opportunity for resistance to develop, enabling vets to promote the responsible use of antimicrobials as Forcyl enters the mutant selection window (MSW) for a very short period of time.”

View your activity >

Leave a Reply

Be the First to Comment!

Notify of
avatar

wpDiscuz